Herpes Simplex Virus Treatment Market by Type (Herpes simplex virus-1 infection and Herpes simplex virus-2 infection), Drug type (Acyclovir, Valacyclovir and Famciclovir), Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027

Herpes simplex virus is one of the highly usual sexually transmitted infections (STIs). It is a viral infection which affects humans. There are two forms of herpes simplex virus such as herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). HSV-1 is commonly related to oral herpes or cold sores. It may also leads to genital herpes through oral sex. HSV-2 is typically related to genital herpes and also causes oral herpes through oral sex. Rise and innovations in the pharmaceutical industry for the production of herpes simplex virus drugs generates an opportunity for the herpes simplex virus treatment market. Surge in awareness regarding the risks and problems of herpes simplex virus infection have resulted in an increased demand for effective treatments. This has resulted in high screening and diagnosis of HSV infection, further propelling the growth of the market. On the contrary, the social stigma related with sexually transmitted diseases, along with the surging product recalls? are factors restraining market. The Herpes Simplex Virus Treatment Market is likely to grow at a rate of 2.0% CAGR by 2027.

Herpes Simplex Virus Treatment Market by Type

Herpes simplex virus-1 infection

Herpes simplex virus-2 infection

Herpes Simplex Virus Treatment Market by Drug type

Acyclovir

Valacyclovir

Famciclovir

Herpes Simplex Virus Treatment Market by Distribution channel

Hospital pharmacies

Drug store and retail pharmacies

Online providers

Herpes Simplex Virus Treatment Market by Geography

North America

Europe

Asia Pacific

Rest of the World

The type segmentation is segmented as Herpes simplex virus-1 infection and Herpes simplex virus-2 infection. Herpes simplex virus-1 infection segment holds the vital share in the market. The rising incidence of Herpes simplex virus-1 infection is a key factor for the vital share of the segment. Furthermore, the rising pressure of Herpes simplex virus-1 encephalitis (HSE), a rare neurological disorder caused by the virus, is projected to augment the growth of the segment.

The Drug type segmentation is classified into Acyclovir, Valacyclovir and Famciclovir. The Valacyclovir segment has the maximum share in the market. This is owing to the availability, cost-effectiveness and effectiveness provided by valacyclovir in stopping the herpes virus from reproducing in the body, thus helping to reduce the symptoms of a herpes outbreak. Further, the valacyclovir is highly used for cold sores ascribed to its extensive absorption rate as acyclovir is broken down by the liver easily when consumed orally.

Based on distribution channel segmentation, the market is divided into Hospital Pharmacies, Drug Store and Retail Pharmacies and Online Providers. Hospital Pharmacies segment held the dominant share in the market. Since, these pharmacies are the major centers for the diagnosis and treatment of patients suffering from herpes infections in both developed and developing nations.

North America region is leading the market share on the basis of geography. The leading share of the segment is accredited to the increased consumption of branded herpes drugs, rising healthcare expenditure, rising introduction of generics, beneficial reimbursement policies and rising disease prevalence in the region are the key factors.

Furthermore, the increasing global health expenditure and government support to fulfill the surging demand for effective therapeutics are promoting companies to engage in creating new and innovative medicines. For example, in June 2021, Innovative Molecules GmbH, a Munich-based drug development company, declared positive results of its new drug candidate, IM-250, a second-generation helicase-primase inhibitor of HSV-1 and HSV-2 in different animal models of HSV. The company received USD 23.8 million in series A equity funding led by Life Sciences Partners and projects commencing Phase 1 clinical trials of IM-250 in late 2022 or early 2023.

The major leading companies of the herpes simplex virus treatment market are Viatris Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius SE and Co. KGaA, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Emcure Pharmaceuticals Limited

Therefore, the herpes simplex virus is the disease which does not have a complete treatment but the medications are available which are playing a significant part in suppressing the frequency and quantity of genital herpes among people. Moreover, the awareness has increased among people regarding the herpes simplex virus which has increased the market demand.

An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.

Detailed information about the attributes which are generating growth in the herpes simplex virus treatment market in the forecast period.

An exact estimation of the herpes simplex virus treatment market share and its contribution to the parent market is provided in the report.

Further profiles of leading competitors and their dynamic strategies are also covered in the study.

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Type: Market Size & Analysis
5.1. Overview
5.2. Herpes simplex virus-1 infection
5.3. Herpes simplex virus-2 infection
6. Drug type: Market Size & Analysis
6.1. Overview
6.2. Acyclovir
6.3. Valacyclovir
6.4. Famciclovir
7. Distribution channel: Market Size & Analysis
7.1. Overview
7.2. Hospital pharmacies
7.3. Drug store and retail pharmacies
7.4. Online providers
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Viatris Inc.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Amneal Pharmaceuticals LLC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Glenmark Pharmaceuticals Limited
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Fresenius SE and Co. KGaA
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Teva Pharmaceutical Industries Ltd.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. Abbott Laboratories
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. GlaxoSmithKline plc
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Pfizer Inc.
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Novartis AG
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Emcure Pharmaceuticals Limited
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

TABLE 1. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR ACYCLOVIR, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR VALACYCLOVIR, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR FAMCICLOVIR, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 16. U.S HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 17. U.S HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 19. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 20. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 22. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 23. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 24. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 26. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 27. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 29. U.K HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 30. U.K HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 32. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 33. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 35. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 36. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 38. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 39. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 41. ROE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 42. ROE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 44. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 48. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 49. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 51. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 52. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 54. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 55. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 57. REST OF APAC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 60. REST OF WORLD HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 63. VIATRIS INC.: FINANCIALS
TABLE 64. VIATRIS INC.: PRODUCTS & SERVICES
TABLE 65. VIATRIS INC.: RECENT DEVELOPMENTS
TABLE 66. AMNEAL PHARMACEUTICALS LLC: FINANCIALS
TABLE 67. AMNEAL PHARMACEUTICALS LLC: PRODUCTS & SERVICES
TABLE 68. AMNEAL PHARMACEUTICALS LLC: RECENT DEVELOPMENTS
TABLE 69. GLENMARK PHARMACEUTICALS LIMITED: FINANCIALS
TABLE 70. GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS & SERVICES
TABLE 71. GLENMARK PHARMACEUTICALS LIMITED: RECENT DEVELOPMENTS
TABLE 72. FRESENIUS SE AND CO. KGAA: FINANCIALS
TABLE 73. FRESENIUS SE AND CO. KGAA: PRODUCTS & SERVICES
TABLE 74. FRESENIUS SE AND CO. KGAA: RECENT DEVELOPMENTS
TABLE 75. TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS
TABLE 76. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 77. TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 78. ABBOTT LABORATORIES: FINANCIALS
TABLE 79. ABBOTT LABORATORIES: PRODUCTS & SERVICES
TABLE 80. ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 81. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 82. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 83. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 84. PFIZER INC.: FINANCIALS
TABLE 85. PFIZER INC.: PRODUCTS & SERVICES
TABLE 86. PFIZER INC.: RECENT DEVELOPMENTS
TABLE 87. NOVARTIS AG: FINANCIALS
TABLE 88. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 89. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 90. EMCURE PHARMACEUTICALS LIMITED: FINANCIALS
TABLE 91. EMCURE PHARMACEUTICALS LIMITED: PRODUCTS & SERVICES
TABLE 92. EMCURE PHARMACEUTICALS LIMITED: RECENT DEVELOPMENTS

Name*

Email ID*

Company*

Phone (With Country Code)*

What is/are your question(s)?:

Publisher: IHR Insights

Related Reports

Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)

Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)

Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)

Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035

Why Market Study Report?

Best Price for Reports
Large Report Database
Easily Customize Reports
24/7 Email & Phone Support